Search Technologies

Showing 1-5 of 5 results found

Bac-2-the-Future: An Improved System for Production of Recombinant Baculovirus

The National Cancer Institute (NCI) seeks licensing of Bac-2-the-Future, an improved system for the production of recombinant baculovirus.

Research Materials

Cell Lines Expressing Nuclear and/or Mitochondrial RNAse H1

The National Institute of Child Health & Human Development (NICHD), Program in Genomics of Differentiation, seeks interested parties to further co-develop small molecule inhibitors of RNase H1, especially in regards to genome instability, transcription, and translation.

Research Materials

New Insect Sf9-ET Cell Line for Determining Baculovirus Titers

The National Cancer Institute (NCI) seeks licensing partners for a novel modified insect cell line, Sf9-ET, that can quickly and efficiently determine baculovirus titers during the expression of recombinant proteins from a baculovirus-based protein expression system.

Research Materials

The Biospecimen Pre-analytical Variables (BPV) Program

The Biorepositories and Biospecimen Research Branch (BBRB) at the National Cancer Institute (NCI) has sponsored various initiatives for conducting biospecimen research. Through these initiatives, NCI seeks to advance biospecimen science and improve research reproducibility by investigating how different biospecimen collection, handling and processing procedures affect biospecimen molecular profiles. BBRB is seeking collaborators to extend these studies.

Therapeutics
Vaccines
Diagnostics
Research Materials

Tni-FNL: An Improved Trichoplusia Ni Cell Line for Protein Expression

Researchers at the National Cancer Institute (NCI) seek licensing for an improved cell line called Tni-FNL which is capable of high level expression of heterologous proteins using baculovirus expression systems.

Research Materials

You are here

Product Type

Development Stage

Therapeutic Area

Institutes and Centers